The treatment of AML: Current status and novel approaches

The epidemiology of AML suggests that in Western countries the median age of patients is around 65 years. Convention in recent years has often resulted in collaborative groups designing trials for patients under or over 60 years. In the former group treatment options included consolidation with stem cell transplantation of matched sibling allograft or autologous cells collected earlier in remission, which was not considered feasible in older patients.